Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Nurix Therapeutics Inc (NRIX)

Nurix Therapeutics Inc (NRIX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,019,392
  • Shares Outstanding, K 49,151
  • Annual Sales, $ 76,990 K
  • Annual Income, $ -143,950 K
  • 60-Month Beta 2.17
  • Price/Sales 13.06
  • Price/Cash Flow N/A
  • Price/Book 6.06
Trade NRIX with:

Options Overview Details

View History
  • Implied Volatility 92.59% ( -4.54%)
  • Historical Volatility 83.59%
  • IV Percentile 45%
  • IV Rank 45.31%
  • IV High 193.55% on 12/04/23
  • IV Low 8.94% on 03/19/24
  • Put/Call Vol Ratio 1.45
  • Today's Volume 169
  • Volume Avg (30-Day) 182
  • Put/Call OI Ratio 1.16
  • Today's Open Interest 2,056
  • Open Int (30-Day) 1,516

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 05/31/24
See More
  • Average Estimate -0.66
  • Number of Estimates 6
  • High Estimate -0.47
  • Low Estimate -0.78
  • Prior Year -0.45
  • Growth Rate Est. (year over year) -46.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
14.44 +44.53%
on 06/17/24
22.44 -6.99%
on 06/25/24
+5.33 (+34.30%)
since 05/28/24
3-Month
11.90 +75.38%
on 04/30/24
22.44 -6.99%
on 06/25/24
+6.17 (+41.97%)
since 03/28/24
52-Week
4.22 +394.55%
on 10/26/23
22.44 -6.99%
on 06/25/24
+10.75 (+106.23%)
since 06/28/23

Most Recent Stories

More News
Biotech Advances Propel Oncology Market to $564.5B Amid Youth Cancer Spike

/CNW/ -- USA News Group News Commentary – The potential threat of cancer looms for everyone, but now new studies are revealing an increased number of cancer...

ONCY : 0.9900 (-1.98%)
ONC.TO : 1.35 (-2.17%)
MBIO : 0.4730 (+1.59%)
LEGN : 44.29 (-0.83%)
JNJ : 146.16 (+0.25%)
NRIX : 20.87 (+0.63%)
Oncology Market Rising Towards $564.5B Amid Cancer Spike and Biotech Innovations

VANCOUVER – USA News Group News Commentary – The potential threat of cancer looms for everyone, but now new studies are revealing an increased number of cancer cases in younger age groups than before....

ONCY : 0.9900 (-1.98%)
ONC.TO : 1.35 (-2.17%)
MBIO : 0.4730 (+1.59%)
LEGN : 44.29 (-0.83%)
JNJ : 146.16 (+0.25%)
NRIX : 20.87 (+0.63%)
Gilead Exercises Option to License Nurix’s IRAK4 Targeted Protein Degrader Development Candidate, NX-0479

Gilead Sciences, Inc. (Nasdaq: GILD) and Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation therapies, today announced that Gilead...

GILD : 68.61 (-0.32%)
NRIX : 20.87 (+0.63%)
Stifel Nicolaus Remains a Buy on Nurix Therapeutics (NRIX)

Stifel Nicolaus analyst Stephen Willey maintained a Buy rating on Nurix Therapeutics (NRIX – Research Report) yesterday and set a price target of $37.00. The company's shares closed last Tuesday at $15.97....

NRIX : 20.87 (+0.63%)
H.C. Wainwright Keeps Their Buy Rating on Nurix Therapeutics (NRIX)

H.C. Wainwright analyst Robert Burns reiterated a Buy rating on Nurix Therapeutics (NRIX – Research Report) today and set a price target of $54.00. The company's shares closed last Friday at $17.71....

NRIX : 20.87 (+0.63%)
Nurix Therapeutics Announces $40 Million Registered Direct Offering

SAN FRANCISCO, July 08, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted...

NRIX : 20.87 (+0.63%)
Nurix Therapeutics Announces $55 Million Registered Direct Offering

SAN FRANCISCO, July 07, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted...

NRIX : 20.87 (+0.63%)
Nurix Therapeutics Reports Fiscal Second Quarter 2022 Financial Results and Provides a Corporate Update

NX-2127 advanced to Phase 1b in CLL based on promising data in Phase 1a clinical trial First patient dosed in NX-5948 Phase 1a clinical trial for certain...

NRIX : 20.87 (+0.63%)
Nurix Therapeutics Announces Clearance of Investigational New Drug Application For NX-1607 Supporting Plans to Expand Enrollment to U.S. Clinical Sites

NX-1607 is being evaluated in multiple immuno-oncology indications, including a range of solid tumor types Phase 1 clinical trial now enrolling patients...

NRIX : 20.87 (+0.63%)
Nurix Therapeutics Will Present Trial in Progress Posters for Two Clinical Programs at the 2022 Annual European Hematology Association (EHA) Congress

Posters provide background information and trial designs for ongoing clinical studies of wholly-owned NX-2127 and NX-5948 programs...

NRIX : 20.87 (+0.63%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Nurix Therapeutics Inc.is a biopharmaceutical company. It focuses on the discovery, development and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company's product candidates include NX-2127 and NX-1607 which are in clinical stage. Nurix Therapeutics...

See More

Key Turning Points

3rd Resistance Point 22.47
2nd Resistance Point 21.70
1st Resistance Point 21.29
Last Price 20.87
1st Support Level 20.11
2nd Support Level 19.34
3rd Support Level 18.93

See More

52-Week High 22.44
Last Price 20.87
Fibonacci 61.8% 15.48
Fibonacci 50% 13.33
Fibonacci 38.2% 11.18
52-Week Low 4.22

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar